Bank of Montreal’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-300
| Closed | -$6K | – | 4364 |
|
|
2024
Q2 | $6K | Hold |
300
| – | – | ﹤0.01% | 3703 |
|
|
2024
Q1 | $5.7K | Hold |
300
| – | – | ﹤0.01% | 3728 |
|
|
2023
Q4 | $5.99K | Hold |
300
| – | – | ﹤0.01% | 3839 |
|
|
2023
Q3 | $5.92K | Sell |
300
-335
| -53% | -$6.54K | ﹤0.01% | 3659 |
|
|
2023
Q2 | $13.5K | Hold |
635
| – | – | ﹤0.01% | 3775 |
|
|
2023
Q1 | $13.5K | Sell |
635
-478
| -43% | -$10.7K | ﹤0.01% | 3583 |
|
|
2022
Q4 | $25.9K | Hold |
1,113
| – | – | ﹤0.01% | 3654 |
|
|
2022
Q3 | $30 | Buy |
1,113
+670
| +151% | +$16.3K | ﹤0.01% | 3739 |
|
|
2022
Q2 | $10 | Sell |
443
-800
| -64% | -$19K | ﹤0.01% | 3861 |
|
|
2022
Q1 | $35K | Hold |
1,243
| – | – | ﹤0.01% | 3846 |
|
|
2021
Q4 | $50K | Hold |
1,243
| – | – | ﹤0.01% | 3240 |
|
|
2021
Q3 | $55K | Hold |
1,243
| – | – | ﹤0.01% | 3548 |
|
|
2021
Q2 | $50K | Buy |
1,243
+400
| +47% | +$14.9K | ﹤0.01% | 3422 |
|
|
2021
Q1 | $29K | Buy |
843
+143
| +20% | +$5.36K | ﹤0.01% | 3920 |
|
|
2020
Q4 | $24K | Hold |
700
| – | – | ﹤0.01% | 4340 |
|
|
2020
Q3 | $20K | Buy |
+700
| New | +$20.6K | ﹤0.01% | 3847 |
|
Other funds holding GERM
Bank of Montreal's GERM Position: Q3 2024 in Review
Bank of Montreal sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 300 shares — an estimated $6K sold.
Bank of Montreal first reported a position in GERM in Q3 2020 and held it in 16 quarters. The position peaked at $55K in Q3 2021. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.
- Bank of Montreal reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
- Bank of Montreal sold 300 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $6K.
- Bank of Montreal first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 16 quarters.
- Bank of Montreal's Amplify Treatments, Testing and Advancements ETF position peaked at $55K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.
Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.